(19)
(11) EP 3 315 136 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.05.2021 Bulletin 2021/18

(45) Mention of the grant of the patent:
31.03.2021 Bulletin 2021/13

(21) Application number: 16814119.0

(22) Date of filing: 02.06.2016
(51) International Patent Classification (IPC): 
A61K 45/00(2006.01)
A61K 48/00(2006.01)
A61P 35/02(2006.01)
A61K 39/395(2006.01)
A61K 31/713(2006.01)
A61P 35/00(2006.01)
A61P 43/00(2006.01)
A61K 39/00(2006.01)
(86) International application number:
PCT/JP2016/066393
(87) International publication number:
WO 2016/208348 (29.12.2016 Gazette 2016/52)

(54)

CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD

KREBSTHERAPEUTIKUM UND VERFAHREN ZUR BEHANDLUNG VON KREBS

MÉDICAMENT THÉRAPEUTIQUE CONTRE LE CANCER ET PROCÉDÉ DE TRAITEMENT DU CANCER


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 25.06.2015 JP 2015128139

(43) Date of publication of application:
02.05.2018 Bulletin 2018/18

(73) Proprietors:
  • National University Corporation Kumamoto University
    Kumamoto-shi, Kumamoto 860-8555 (JP)
  • Tokyo Institute of Technology
    Tokyo 152-8550 (JP)

(72) Inventor:
  • NIIMORI Kanako
    Kumamoto-shi Kumamoto 860-8555 (JP)

(74) Representative: Sommer, Andrea 
Andrea Sommer Patentanwälte PartG mbB Uhlandstraße 2
80336 München
80336 München (DE)


(56) References cited: : 
WO-A1-2012/103455
   
  • S. LEE ET AL: "Aurora A Is a Repressed Effector Target of the Chromatin Remodeling Protein INI1/hSNF5 Required for Rhabdoid Tumor Cell Survival", CANCER RESEARCH, vol. 71, no. 9, 26 April 2011 (2011-04-26) , pages 3225-3235, XP055540570, US ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-2167
  • H. LIN ET AL: "Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma", CLINICAL CANCER RESEARCH, vol. 15, no. 20, 6 October 2009 (2009-10-06), pages 6404-6411, XP055540664, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-1135
  • KIMBERLY H. KIM ET AL: "Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth", CANCER GENETICS, vol. 207, no. 9, 1 September 2014 (2014-09-01), pages 365-372, XP055540558, AMSTERDAM, NL ISSN: 2210-7762, DOI: 10.1016/j.cancergen.2014.04.004
  • P Subbarayalu: "Abstract P4-05-09: Matrin 3: A novel micro-tubule associated RNA binding protein that acts as a potent tumor suppressor | Cancer Research", , 15 May 2015 (2015-05-15), XP055540247, Retrieved from the Internet: URL:http://cancerres.aacrjournals.org/cont ent/75/9_Supplement/P4-05-09# [retrieved on 2019-01-10]
  • PATRYCJA PRZYGODZKA ET AL: "Matrin 3 as a key regulator of endothelial cell survival", EXPERIMENTAL CELL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 317, no. 6, 13 December 2010 (2010-12-13), pages 802-811, XP028170825, ISSN: 0014-4827, DOI: 10.1016/J.YEXCR.2010.12.009 [retrieved on 2010-12-21]
  • KATO H ET AL: "Knock down of hSNF5/Ini1 causes cell cycle arrest and apoptosis in a p53-dependent manner", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 361, no. 3, 28 September 2007 (2007-09-28), pages 580-585, XP022624891, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.07.035 [retrieved on 2007-08-11]
  • B GOLDENSON ET AL: "The aurora kinases in cell cycle and leukemia", ONCOGENE, vol. 34, no. 5, 17 March 2014 (2014-03-17) , pages 537-545, XP055540958, London ISSN: 0950-9232, DOI: 10.1038/onc.2014.14
  • ULBRIGHT TM. ET AL.: 'Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements' MODERN PATHOLOGY vol. 23, 2010, pages 972 - 980, XP055340460
  • CHEN Y. ET AL.: 'hnRNP K expression and its clinical significance in human lung cancer tissues' CHIN J LUNG CANCER vol. 11, no. 2, 01 April 2008, pages 241 - 245, XP055505076
  • SATO M. ET AL.: 'The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14ARF, p16INK4a and RASSF1A in human lung cancer cell lines' ONCOGENE vol. 21, 2002, pages 4822 - 4829, XP055340464
  • OWONIKOKO TK. ET AL.: 'Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer' CANCER RESEARCH vol. 74, no. 19, XP055235773
  • NOBUE KUMAKI ET AL.: 'Hito Seiso Hai Saibo Shuyo ni Okeru Shinkei Naibunpitsu Keishitsu Hatsugen no Kenkyu: Men'eki Soshiki Kagakuteki Shuho Oyobi Kyoshoten Laser Kenbikyo o Mochiita Kento' THE JAPAN SOCIETY OF HISTOCHEMISTRY AND CYTOCHEMISTRY SOKAI · GAKUJUTSU SHUKAI KOEN PROGRAM · YOKOSHU vol. 49 TH, 2008, page 38, XP009507922
  • SAMPETREAN OLTEA ET AL.: 'Tanpakushitsu Rinsanka Koso Sogaiyaku' EXPERIMENTAL MEDICINE vol. 27, no. 5, 2009, pages 642 - 647, XP009507906
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).